Arkolith/Insider Trading/ZYNE/Form 4

Anido Armando

Chairman & Chief Exec. Officer, DirectorZynerba Pharmaceuticals, Inc. (ZYNE) · full profile →Form 4 · filed Jan 25, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$21K
Net Open-Market Flow
-$21K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 24, 2023Grant(A)250K—$0826K
Jan 23, 2023Sell(S)35K$0.60$21K576K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-23-001384) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML